Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)

Key facts

Sponsor

State University of New York - Downstate Medical Center

Principal Investigator

Jacob V Aranda, MD, PhD

SUNY Downstate Medical Center, University Hospital of Brooklyn

Intervention

Caffeine citrate(drug)

Enrollment

14 target

Eligibility

All sexes

Timeline

2015 – 2018

Study locations (1)

• SUNY Downstate Medical Center/University Hospital of Brooklyn, Brooklyn, New York, United States

Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Food and Drug Administration (FDA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Retinopathy of prematurity

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07093255
  Safety, PK and PD of FLQ-101 in Premature Neonates
  FELIQS INC.
• RECRUITINGNCT06612541
  Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT07334652
  Pain and Comfort in the Examination of Retinopathy of Prematurity
  Ataturk University
• RECRUITINGNANCT06717412
  Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
  Wang Yusheng
• RECRUITINGNCT05558059
  Imaging Retinal Vasculature in Infant Eyes
  Duke University
• ACTIVE NOT RECRUITINGNANCT06109285
  Validation of i-ROP DL to Detect More Than Mild ROP
  Siloam Vision
• RECRUITINGNCT06315556
  An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
  Bayer
• RECRUITINGNANCT06694103
  The Effect of Two Non-Pharmacological Methods on Pain During Retinopathy Examination
  Sinem Basdemir

See all trials for Retinopathy of prematurity →